(Bloomberg) -- Permira is nearing a deal to buy U.K.-based blood-plasma firm Bio Products Laboratory Ltd. from China’s Creat Group Corp., according to people familiar with the matter.
The British private equity firm could announce an acquisition in the coming weeks, the people said, asking not to be identified discussing confidential information. Separately, Permira is also considering investing in Italian plasma group Kedrion as part of its larger strategy for the sector, the people said.
No final decisions have been made and there’s no certainty an agreement will be reached, the people said. A representative for Permira declined to comment. Representatives for Creat and Kedrion couldn’t immediately be reached for comment outside regular business hours.
Creat has been working with Bank of America Corp. on the sale, which drew interest from a host of private equity firms, Bloomberg News reported in July.
In September, Grifols SA agreed to buy Creat’s Biotest AG for about 1.6 billion euros ($1.8 billion), pouncing after U.S. regulators pushed back on the Chinese group’s expansion into the blood-plasma industry.
©2021 Bloomberg L.P.